昂利康(002940.SZ)與川寧生物簽訂戰略合作協議
格隆匯10月13日丨昂利康(002940.SZ)公佈,為進一步加強優勢互補和業務協同,在頭孢原料藥全產業鏈上形成合作,近日,公司與伊犁川寧生物技術股份有限公司(以下簡稱“川寧生物”)簽訂了戰略合作協議。
川寧生物應持續做好發酵法生產7-ADCA(系生產頭孢拉定、頭孢氨苄和頭孢羥氨苄所必需的醫藥中間體)的成本控制和工藝改進,並充分利用發酵生產7-ADCA的成本優勢,全力支持昂利康下游原料藥的生產。
昂利康應全力協助川寧生物在7-ADCA建立產品標準、雜質研究、成本控制等方面的工作。昂利康應充分利用川寧生物提供的優勢,為客户提供穩定及有競爭力的產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.